The New Generation Gap: Nationwide survey shows differences

SALT LAKE CITY, Nov. 23, 2021 (GLOBE NEWSWIRE) – One of the biggest problems parents of teenagers can face is determining whether their child is experiencing a mental challenge or normal “growing pains”.

Only half of parents * with children ages 16 to 24 said they were very or completely confident about seeing the difference between normal adolescent challenges and mental illness, according to GeneSight® Mental Health Monitor from Myriad Genetics, Inc. (NASDAQ: MYGN), a leading provider of genetic testing and precision medicine.

In addition, almost every third parent believes that “fear” and “worry” are the same thing.

“Fear and worry are not the same. Concerns are situational. Anxiety is persistent and excessive – and it doesn’t go away when the specific cause of the stress or stress is gone, “said Debbie Thomas, EdD, APRN, based in Louisville, Kentucky. “In my practice I see children and adolescents adults and / or their parents who have inadvertently ignored or minimized the symptoms of anxiety until they turn into a crisis. We achieve the best results if we don’t wait until fear consumes everything and destroys life. “

The importance of communication

The first step in helping your child with mental health problems is communication. However, just over half of parents believe that their child would feel comfortable talking to them about their mental health problems. This is confirmed by the 16- to 24-year-olds * surveyed – one in five said they did not tell anyone about their mental health problems.

“As many teenage parents know, your children can stop confiding in you. However, the GeneSight Mental Health Monitor shows the importance of talking about mental health, “said Mark Pollack, MD, chief medical officer, Mental Health, Myriad Genetics. “If you suspect that your child’s mental health is suffering, speak to them and speak to a doctor about your concerns.”

Seek treatment

Parents can have difficulty identifying and talking about mental health issues, but the GeneSight Mental Health Monitor found that early intervention and treatment can be helpful. Three out of four young adults surveyed who had experienced a mental challenge said they had at least some of their problems before age 18. Almost three quarters of these young adults would like their parents to do so. When asked why:

  • 67% said they didn’t suffer as much in their teenage years
  • 66% said they would be better equipped to deal with their current problems
  • 64% said it prepared them better for growing up

“The transition to adulthood is tough enough – nobody should be struggling with their mental health at the same time,” said Dr. Thomas. “Give your child psychological treatment when they have anxiety so that they can become successful, caring, and well-adjusted adults. This also shows them that it is okay, normal and optimal to seek help at other times in their life if necessary – and is another positive step towards destigmatizing mental health care. “

For more information on how genetic testing can educate clinicians about treating depression, anxiety, ADHD, and other psychiatric conditions, please visit GeneSight.com.

* All mentions of “parents” refer to parents of children aged 16 to 24 years. Likewise, “young adults” consistently refers to respondents aged 16 to 24 years.

About the GeneSight® Mental health monitor

The GeneSight Mental Health Monitor is a nationwide survey of adults in the United States conducted by ACUPOLL Precision Research, Inc. in August-September. 2021 under a statistically representative sample of adults aged 21 and over and a representative sample of parents of young adult children and young adults aged 16-24. The error rate of the survey results for the entire base population with a confidence interval of 95% is +/- 3%.

About the GeneSight® Check

Myriad Genetics’ GeneSight Psychotropic Test is the leading pharmacogenomic test for 61 drugs commonly prescribed for depression, anxiety, ADHD, and other psychiatric conditions. The GeneSight test can educate clinicians about how a patient’s genes may affect metabolism and / or response to certain psychiatric drugs. It has been administered to more than 1.5 million patients by tens of thousands of clinicians to provide genetic information that is unique to each patient. The GeneSight test supplements other information a doctor might consider as part of a comprehensive medical evaluation. Learn more at GeneSight.com.

About Myriad Genetics

Myriad Genetics is a leading genetic testing and precision medicine company committed to promoting health and well-being for all, empowering people with critical genetic knowledge, and empowering healthcare providers to better identify, treat, and prevent disease. Myriad discovers and commercializes genetic tests that determine disease risk, assess risk of disease progression, and guide treatment decisions across medical specialties where critical genetic intelligence can dramatically improve patient care and reduce healthcare costs. For more information, please visit the company’s website: www.myriad.com.

Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice CDx, Vectra, EndoPolarisight, ForScore Predictes are brands, or PrequelScore registered trademarks of Myriad Genetics, Inc. or its wholly-owned subsidiaries in the US and abroad.

Media contact:
Sarah DeDiemar
(513) 701-5162
[email protected]

Investor contact:
Nathan Smith
(801) 505-5067
[email protected]

Source link

About Stephanie McGehee

Check Also

PROG Holdings, Inc. Announces – GuruFocus.com

PROG + Beteiligungen% 2C + Inc. (NYSE: PRG, Financial), the fintech holding company for Progressive …